Novo Holdings A/S - 21 Jun 2021 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
10%+ Owner
Signature
/s/ Peter Haahr, Chief Financial Officer of Novo Holdings A/S
Issuer symbol
VERV
Transactions as of
21 Jun 2021
Net transactions value
+$6,650,000
Form type
4
Filing time
22 Jun 2021, 17:17:32 UTC
Previous filing
17 Jun 2021
Next filing
23 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV COMMON STOCK Conversion of derivative security +443,265 443,265 21 Jun 2021 Direct F1
transaction VERV COMMON STOCK Purchase $6,650,000 +350,000 +79% $19.00 793,265 21 Jun 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV SERIES B CONVERTIBLE PREFERRED STOCK Conversion of derivative security -443,265 -100% 0 21 Jun 2021 COMMON STOCK 443,265 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Novo Holdings A/S is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each share of Series B Convertible Preferred Stock automatically converted into one share of common stock upon the completion of the Issuer's initial public offering. These shares have no expiration date.
F2 Represents a purchase from the underwriters in the Issuer's initial public offering.